SCHEMBL1194641

SCHEMBL1194641

O=C(O)Cc1cnn(-c2ccc(F)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.51
DRD4 P21917 1/20 0.51
DRD3 P35462 1/20 0.51
LMNA P02545 4/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 3/20 0.49
KDM4E B2RXH2 3/20 0.49
RAB9A P51151 3/20 0.49
HPGD P15428 2/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
NR4A1 P22736 1/20 0.49
MPI P34949 1/20 0.49
RECQL P46063 1/20 0.49
ESR2 Q92731 1/20 0.49
FFAR4 Q5NUL3 3/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3814933 0.85 RAB9A (0.63) DRD2DRD4DRD3LMNAALDH1A1
SCHEMBL11486254 0.84 QPCT (0.49) DRD2DRD4DRD3LMNAALDH1A1
SCHEMBL31517615 0.84 MAPT (0.44) DRD2DRD4DRD3LMNAALDH1A1
SCHEMBL19510721 0.84 MAPT (0.49) DRD2DRD4DRD3LMNAALDH1A1
SCHEMBL31517482 0.84 MAPT (0.50) DRD2DRD4LMNAALDH1A1MAPT
SCHEMBL28629989 0.84 DRD4 (0.51) DRD2DRD4DRD3LMNAALDH1A1
SCHEMBL30767750 0.84 MAP4K4 (0.47) DRD2DRD4DRD3LMNARAB9A
SCHEMBL31517715 0.83 MAPT (0.50) DRD2DRD4DRD3LMNAALDH1A1
SCHEMBL31517414 0.82 NPC1 (0.52) DRD2DRD4DRD3LMNAALDH1A1
SCHEMBL31517521 0.82 SMN1; SMN2 (0.46) DRD2DRD4DRD3LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025040546-A1 PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS PROXYGEN GMBH (AT) 2025-02-27 WO disclosed
EP-2155685-B1 PYRAZOLE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LTD (GB) 2011-03-16 EP disclosed
US-20110046137-A1 Pyrazole Derivatives as P2X7 Modulators GLAXO GROUP LIMITED 2011-02-24 US disclosed
EP-2155685-A1 PYRAZOLE DERIVATIVES AS P2X7 MODULATORS Glaxo Group Limited (GB) 2010-02-24 EP disclosed
WO-2008138876-A1 PYRAZOLE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046137-A1 Pyrazole Derivatives as P2X7 Modulators P2RX3, P2RX7, P2RX1 DRD2 2182/4885DRD4 3186/4885DRD3 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.